Research shows sotagliflozin is the first medication of its kind to significantly reduce both heart attacks and strokes
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Medscape15h
Age Affects Efficacy of Popular Diabetes Drugs
A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...
MedPage Today3h
SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease
The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
thecardiologyadvisor.com12h
Empagliflozin, Dapagliflozin Comparably Reduce AKI, CKD Risks in Diabetes Population
Observational data fill a knowledge gap in the absence of randomized trials comparing empagliflozin vs dapagliflozin in patients with type 2 diabetes.
The Lancet2h
Sodium–glucose co-transporter inhibitors—who would have guessed?
Prediction is very difficult, especially about the future”; whether it is the Nobel laureate Niels Bohr or others who have ...
Gesynta Pharma Receives $27 Million For Endometriosis Novel Therapy Drug
Swedish biotech company Gesynta Pharma AB has secured $27 million in a Series B financing round led by Innovestor Life Science in Finland.